Eli Lilly and Company (NYSE:LLY) Price Target Cut to $900.00 by Analysts at Deutsche Bank Aktiengesellschaft

Key Points

• Deutsche Bank Aktiengesellschaft has reduced Eli Lilly's price target from $1,010.00 to $900.00, maintaining a "buy" rating, which suggests a potential upside of 40.65% from the current price.
• Multiple research firms have recently downgraded Eli Lilly, with ratings ranging from "strong-buy" to "reduce", indicating mixed perceptions of the stock's future performance.
• Eli Lilly reported $6.31 earnings per share, exceeding estimates, and achieved $15.56 billion in revenue for the quarter, marking a significant 37.6% increase year-over-year.

Eli Lilly and Company (NYSE:LLY - Get Free Report) had its price objective cut by research analysts at Deutsche Bank Aktiengesellschaft from $1,010.00 to $900.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Deutsche Bank Aktiengesellschaft's target price indicates a potential upside of 40.65% from the stock's current price.

LLY has been the subject of several other research reports. Hsbc Global Res downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a report on Monday, April 28th. Guggenheim increased their target price on shares of Eli Lilly and Company from $936.00 to $942.00 and gave the company a "buy" rating in a report on Friday, July 11th. Leerink Partnrs cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Thursday. HSBC downgraded shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and reduced their target price for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. Finally, Erste Group Bank downgraded shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and an average price target of $977.65.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock traded up $14.24 during trading on Monday, reaching $639.89. The company's stock had a trading volume of 7,306,359 shares, compared to its average volume of 4,048,155. The business's 50-day moving average price is $774.10 and its 200-day moving average price is $799.34. The firm has a market cap of $606.45 billion, a PE ratio of 41.87, a P/E/G ratio of 0.87 and a beta of 0.44. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the firm posted $3.92 earnings per share. The firm's revenue was up 37.6% compared to the same quarter last year. Equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Insider Activity

In other news, Director Jamere Jackson acquired 200 shares of the company's stock in a transaction dated Friday, August 8th. The shares were acquired at an average price of $639.56 per share, with a total value of $127,912.00. Following the purchase, the director directly owned 9,402 shares of the company's stock, valued at $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.13% of the company's stock.

Institutional Trading of Eli Lilly and Company

Hedge funds have recently modified their holdings of the stock. Tobias Financial Advisors Inc. increased its position in shares of Eli Lilly and Company by 4.1% during the fourth quarter. Tobias Financial Advisors Inc. now owns 307 shares of the company's stock worth $237,000 after purchasing an additional 12 shares in the last quarter. Redwood Investments LLC boosted its stake in Eli Lilly and Company by 0.5% during the fourth quarter. Redwood Investments LLC now owns 2,209 shares of the company's stock worth $1,705,000 after buying an additional 12 shares during the last quarter. Hobbs Wealth Management LLC boosted its stake in Eli Lilly and Company by 0.8% during the first quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock worth $1,205,000 after buying an additional 12 shares during the last quarter. Hixon Zuercher LLC boosted its stake in Eli Lilly and Company by 0.7% during the first quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock worth $1,477,000 after buying an additional 12 shares during the last quarter. Finally, O Brien Wealth Partners LLC boosted its stake in Eli Lilly and Company by 25.5% during the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock worth $49,000 after buying an additional 12 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.